JSPR
Jasper Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
0.56
▼ 0.03 (5.52%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.59
Day high
0.60
Day low
0.55
Volume
328.61K
Market cap
$18.64M
P/E (TTM)
—
52W range
0.32 – 2.69
Trailing performance
Returnvs SPY
1W
-10.40%
-12.3%
1M
-21.02%
-22.2%
3M
+8.74%
+4.2%
6M
-16.17%
-34.4%
YTD
-69.40%
-83.6%
1Y
-77.51%
-93.9%
3Y
-92.00%
-174.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on JSPR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 22, 25 | MARTELL RONALD A Chief Executive Officer |
BUY | 41.00K | $99.63K | Direct |
| Sep 22, 25 | WIGGANS THOMAS G Director |
BUY | 41.00K | $99.63K | Indirect |
| Sep 22, 25 | LUCAS SVETLANA Director |
BUY | 20.00K | $48.60K | Direct |
| Sep 22, 25 | SHIZURU JUDITH ANNE M.D., PH.D. Director |
BUY | 41.00K | $99.63K | Direct |
| Dec 12, 24 | MAHAL JEETINDER SINGH Chief Operating Officer |
SELL | 900 | $19.90K | Direct |
| Dec 12, 24 | MAHAL JEETINDER SINGH Chief Operating Officer |
CONVERSION | 900 | $6.39K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
LUCAS SVETLANA |
Director | 20.00K | Purchase |
MAHAL JEETINDER SINGH |
Chief Operating Officer | 25.01K | Sale |
MARTELL RONALD A |
Chief Executive Officer | 74.12K | Purchase |
SHIZURU JUDITH ANNE M.D., PH.D. |
Director | 156.90K | Purchase |
WIGGANS THOMAS G |
Director | — | Purchase |
Fundamentals
Market cap$18.64M
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)$-1.04
Free cash flow—
Total cash—
Total debt—
Book value / share$0.05
Shares outstanding33.27M
Float—
Short % of float17.78%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.22
PEG ratio—
Price / sales—
Price / book11.20
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $63.10M | $55.82M | $51.78M | $34.63M | +13.0% |
| Selling, general & admin | $20.78M | $20.42M | $17.08M | $16.57M | +1.8% |
| Total operating expense | $83.88M | $76.24M | $68.86M | $51.20M | +10.0% |
| Operating income | -$83.88M | -$76.24M | -$68.86M | -$51.20M | -10.0% |
| Net interest income | $1.74M | $5.06M | $5.20M | $701.00K | -65.6% |
| Pre-tax income | -$75.80M | -$71.27M | -$64.47M | -$37.69M | -6.4% |
| Net income | -$75.80M | -$71.27M | -$64.47M | -$37.69M | -6.4% |
| Net income to common | -$75.80M | -$71.27M | -$64.47M | -$37.69M | -6.4% |
| Basic EPS | -3.95 | -4.89 | -6.18 | -10.30 | +19.2% |
| Diluted EPS | -3.95 | -4.89 | -6.18 | -10.30 | +19.2% |
| EBIT | -$83.88M | -$76.24M | -$68.86M | -$51.20M | -10.0% |
| EBITDA | -$82.83M | -$74.87M | -$67.75M | -$50.22M | -10.6% |
| Basic shares | 19.17M | 14.58M | 10.44M | 3.65M | +31.4% |
| Diluted shares | 19.17M | 14.58M | 10.44M | 3.65M | +31.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $28.69M | $71.64M | $86.89M | $38.25M | -59.9% |
| Cash & short-term investments | $28.69M | $71.64M | $86.89M | $38.25M | -59.9% |
| Total current assets | $34.65M | $75.81M | $88.94M | $41.73M | -54.3% |
| Property, plant & equipment | $604.00K | $2.85M | $4.19M | $5.45M | -78.8% |
| Total assets | $35.78M | $79.90M | $94.89M | $48.36M | -55.2% |
| Total current liabilities | $13.20M | $15.24M | $12.37M | $7.07M | -13.4% |
| Total debt | $1.24M | $1.81M | $2.79M | $3.65M | -31.9% |
| Total liabilities | $31.63M | $18.23M | $16.45M | $12.37M | +73.5% |
| Retained earnings | -$316.67M | -$240.87M | -$169.60M | -$105.14M | -31.5% |
| Shareholder equity | $4.15M | $61.67M | $78.44M | $35.99M | -93.3% |
| Working capital | $21.45M | $60.57M | $76.56M | $34.67M | -64.6% |
| Net tangible assets | $4.15M | $61.67M | $78.44M | $35.99M | -93.3% |
| Shares issued | 28.00M | 15.02M | 11.16M | 3.80M | +86.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$75.80M | -$71.27M | -$64.47M | -$37.69M | -6.4% |
| Depreciation & amortisation | $1.06M | $1.37M | $1.11M | $975.00K | -23.1% |
| Stock-based compensation | $6.71M | $6.62M | $5.21M | $4.09M | +1.4% |
| Change in working capital | -$4.92M | $184.00K | $5.10M | -$649.00K | -2,775.5% |
| Operating cash flow | -$77.16M | -$62.60M | -$52.07M | -$45.86M | -23.3% |
| Capital expenditure | -$7.00K | -$552.00K | -$267.00K | -$576.00K | +98.7% |
| Investing cash flow | $5.00K | -$532.00K | -$267.00K | -$576.00K | +100.9% |
| Financing cash flow | $34.21M | $47.88M | $100.97M | $55.00K | -28.6% |
| Free cash flow | -$77.17M | -$63.15M | -$52.33M | -$46.43M | -22.2% |
| End cash position | $29.11M | $72.05M | $87.30M | $38.67M | -59.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $5.13M | $5.81M | $11.36M | $14.39M | $21.20M | -11.7% |
| Selling, general & admin | $4.07M | $5.14M | $4.48M | $4.78M | $5.88M | -20.7% |
| Total operating expense | $9.21M | $10.95M | $15.84M | $19.17M | $27.08M | -15.9% |
| Operating income | -$9.21M | -$10.95M | -$15.84M | -$19.17M | -$27.08M | +15.9% |
| Net interest income | $82.00K | $164.00K | $338.00K | $342.00K | $437.00K | -50.0% |
| Pre-tax income | -$2.76M | -$1.17M | -$9.10M | -$18.74M | -$26.72M | -135.1% |
| Net income | -$2.76M | -$1.17M | -$9.10M | -$18.74M | -$26.72M | -135.1% |
| Net income to common | -$2.76M | -$1.17M | -$9.10M | -$18.74M | -$26.72M | -135.1% |
| Basic EPS | -0.10 | -0.04 | -0.32 | -1.13 | -1.74 | -150.0% |
| Diluted EPS | -0.10 | -0.04 | -0.32 | -1.13 | -1.74 | -150.0% |
| EBIT | -$9.21M | -$10.95M | -$15.84M | -$19.17M | -$27.08M | +15.9% |
| EBITDA | -$9.19M | -$10.93M | -$15.55M | -$18.94M | -$26.82M | +16.0% |
| Basic shares | 28.70M | 28.67M | 28.66M | 16.64M | 15.33M | +0.1% |
| Diluted shares | 28.70M | 28.67M | 28.66M | 16.64M | 15.33M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.31M | $14.14M | $28.69M | $50.90M | $39.51M | -48.3% |
| Cash & short-term investments | $7.31M | $14.14M | $28.69M | $50.90M | $39.51M | -48.3% |
| Total current assets | $11.57M | $20.29M | $34.65M | $54.56M | $42.97M | -43.0% |
| Property, plant & equipment | $188.00K | $398.00K | $604.00K | $2.34M | $2.89M | -52.8% |
| Total assets | $11.80M | $21.18M | $35.78M | $57.47M | $46.47M | -44.3% |
| Total current liabilities | $7.84M | $9.00M | $13.20M | $21.04M | $20.50M | -12.8% |
| Total debt | $270.00K | $757.00K | $1.24M | $1.70M | $2.15M | -64.3% |
| Total liabilities | $10.39M | $17.78M | $31.63M | $45.90M | $22.96M | -41.6% |
| Retained earnings | -$320.60M | -$317.84M | -$316.67M | -$307.57M | -$288.83M | -0.9% |
| Shareholder equity | $1.41M | $3.40M | $4.15M | $11.57M | $23.50M | -58.4% |
| Working capital | $3.73M | $11.30M | $21.45M | $33.52M | $22.47M | -67.0% |
| Net tangible assets | $1.41M | $3.40M | $4.15M | $11.57M | $23.50M | -58.4% |
| Shares issued | 28.08M | 28.00M | 28.00M | 27.98M | 16.22M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$2.76M | -$1.17M | -$9.10M | -$18.74M | -$26.72M | — | -135.1% |
| Depreciation & amortisation | $21.00K | $21.00K | $290.00K | $229.00K | $258.00K | — | 0.0% |
| Stock-based compensation | $764.00K | $423.00K | $1.66M | $1.42M | $1.82M | — | +80.6% |
| Change in working capital | $1.19M | -$4.36M | -$9.73M | -$187.00K | $8.88M | — | +127.3% |
| Operating cash flow | -$6.92M | -$14.55M | -$21.87M | -$17.00M | -$15.45M | — | +52.4% |
| Investing cash flow | $80.00K | $0 | $0 | $0 | $1.00K | — | — |
| Financing cash flow | — | — | -$340.00K | $28.39M | $6.16M | $0 | — |
| Free cash flow | -$6.92M | -$14.55M | -$21.87M | -$17.00M | -$15.46M | — | +52.4% |
| End cash position | $7.73M | $14.56M | $29.11M | $51.32M | $39.93M | — | -46.9% |
Options analytics
Put / call volume
0.14
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.00
+257.1% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+25.0%
Puts bid over calls
Call volume
229
Contracts, this expiry
Put volume
31
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
2.00
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $12.00M | — |
| Next year | — | — | $0 | -100.0% |
Analyst targets & ownership
Mean target$20.00
High target$20.00
Low target$20.00
Implied upside3470.79%
Analyst count1
ConsensusSTRONG BUY
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders2.86%
Held by institutions39.27%
Institutions holding54
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.59
-5.20% from price
SMA 20
0.61
-8.44% from price
SMA 50
0.67
-16.90% from price
SMA 100
0.65
-13.59% from price
SMA 200
0.96
-41.92% from price
EMA 12
0.60
-6.10% from price
EMA 26
0.62
-10.35% from price
EMA 50
0.65
-13.94% from price
RSI (14)
40.4
Neutral
MACD (12,26,9)
-0.03
Hist -0.00
ATR (14)
0.06
11.01% of price
Realised vol 30D
68.3%
Annualised
Bollinger upper
0.69
20, 2σ
Bollinger lower
0.53
20, 2σ
50 / 200 cross
Death
0.67 vs 0.96
Trend bias
Below 200
-41.92%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.71
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
68.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-86.9%
Peak to trough
Max drawdown 5Y
-99.8%
Peak to trough
ATR 14
0.06
11.01% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
5.81M
Prior 5.36M
Change vs prior
+8.4%
Shorts adding
% of float
17.78%
Elevated
% of shares out
17.46%
Against total outstanding
Days to cover
10.5
Crowded exit
Float
—
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 26 | Piper Sandler | INITIATED | — | Overweight |
| May 15, 26 | TD Cowen | DOWNGRADE | Buy | Hold |
| May 15, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Apr 1, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Nov 11, 25 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Sep 22, 25 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Sep 22, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Sep 22, 25 | BTIG | MAINTAINED | Buy | Buy |
| Aug 15, 25 | UBS | MAINTAINED | Buy | Buy |
| Jul 8, 25 | BMO Capital | DOWNGRADE | Outperform | Market Perform |
| Jul 8, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Jul 8, 25 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateJan 4, 2024
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K/A · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-09-28
Notification filed by national security exchange to report the removal from listing and registration of matured
25-NSE · 2026-09-24
Proxy Statements
DEF 14A · 2026-09-04
Corporate Changes & Voting Matters
8-K · 2026-08-26
Proxy Statements
PRE 14A · 2026-08-24
Corporate Changes & Voting Matters
8-K · 2026-08-14
Headlines
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
GlobeNewswire · 22d ago
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 28d ago
Jasper Therapeutics beats Q2 expectations but shares fall after results
InvestorsHub · 51d ago
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 54d ago
Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target
MT Newswires · 56d ago
Jasper gets a lifeline in merger with immune drugmaker Kira
BioPharma Dive · 82d ago
Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall
MT Newswires · 83d ago
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
GlobeNewswire · 83d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.